Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab ; volume:23 ; number:1 ; day:10 ; month:6 ; year:2023 ; pages:1-7 ; date:12.2023
BMC urology ; 23, Heft 1 (10.6.2023), 1-7, 12.2023

Creator
Matsumura, Soichi
Kato, Taigo
Kujime, Yuma
Kitakaze, Hiroaki
Nakano, Kosuke
Hongo, Sachiko
Yoshioka, Iwao
Okumi, Masayoshi
Nonomura, Norio
Takada, Shingo
Contributor
SpringerLink (Online service)

DOI
10.1186/s12894-023-01248-z
URN
urn:nbn:de:101:1-2023091910213431674352
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Matsumura, Soichi
  • Kato, Taigo
  • Kujime, Yuma
  • Kitakaze, Hiroaki
  • Nakano, Kosuke
  • Hongo, Sachiko
  • Yoshioka, Iwao
  • Okumi, Masayoshi
  • Nonomura, Norio
  • Takada, Shingo
  • SpringerLink (Online service)

Other Objects (12)

Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab

Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma

Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection

Related objects